Linaglip Tablet
Linagliptin
5mg
Asian Pharmaceuticals Pvt. Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Linaglip Tablet is used for:
Type 2 Diabetes Mellitus
Adult Dose
Oral
Type 2 diabetes mellitus
Adult: 5 mg once daily.
Indicated for adults with diabetes mellitus type II along with diet and exercise to lower blood sugar; may be used as monotherapy or in combination with other common antidiabetic medications including metformin, sulfonylurea, pioglitazone, or insulin.
Elderly: No dose adjustment is necessary based on age.
Hepatic or renal impairment: No dosage adjustment required.
Child Dose
Safety and efficacy not established
Renal Dose
Renal Impairment: No dose adjustment.
Administration
May administer with or without food
Contra Indications
Patients with a history of a hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyperreactivity. Type 1 DM. Treatment of diabetic ketoacidosis.
Precautions
Concomitant use w/ sulphonylureas which are known to cause hypoglycemia; dose reduction of sulphonylureas may be considered. May affect ability to drive or operate machinery. Childn. Elderly >75 yr. Pregnancy & lactation.
Lactation: Unknown whether distributed in breast milk; caution advised
Pregnancy-Lactation
Interactions
Increased risk of hypoglycaemia when used w/ an insulin secretagogue (e.g. sulfonylurea) or insulin. Plasma concentration of linagliptin may be decreased by strong inducers of P-glycoprotein (e.g. rifampicin) and may be increased by strong P-glycoprotein inhibitors (e.g. ritonavir).
Adverse Effects
Side effects of Linagliptin :
1-10%
Nasopharyngitis (4.3%),Hyperlipidemia (2.8%; with pioglitazone),Cough (2.4%; with metformin and sulfonylurea),Hypertriglyceridemia (2.4%; with sulfonylurea),Weight gain (2.3%; with pioglitazone),
Hypoglycemia 7.6% overall incidence, 22.9% incidence compared with placebo plus metformin and a sulfonylurea
Incidence similar to placebo with monotherapy or combined with metformin or pioglitazone
Mechanism of Action
Dipeptidyl peptidase 4 (DPP-4) inhibitor; increases and prolongs incretin hormone activity which is inactivated by DPP-4 enzyme.
Incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells .
Note
Linaglip 5mg Tablet manufactured by Asian Pharmaceuticals Pvt. Ltd.. Its generic name is Linagliptin. Linaglip is availble in Nepal.
Farmaco Nepal drug index information on Linaglip Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.